b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31282805</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>07</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1029-2403</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>60</Volume>\n                    <Issue>14</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>12</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Leukemia &amp; lymphoma</Title>\n                <ISOAbbreviation>Leuk. Lymphoma</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Occurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>3503-3511</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/10428194.2019.1636984</ELocationID>\n            <Abstract>\n                <AbstractText>Forty-three chromosomal abnormalities in Philadelphia-negative metaphases (Ph-CAs) appeared in 35 of 432 patients in chronic phase chronic myeloid leukemia (CP-CML) undergoing tyrosine kinase inhibitor (TKI) treatments. These CAs were mostly common in trisomy-8 (16 cases), trisomy-Y (five cases), and monosomy-7 (five cases). Furthermore, Ph- CAs were significantly associated with higher platelet count (494\xe2\x80\x89\xc3\x97\xe2\x80\x8910<sup>9</sup>/L vs. 326\xe2\x80\x89\xc3\x97\xe2\x80\x8910<sup>9</sup>/L, <i>p</i>\xe2\x80\x89=\xe2\x80\x89.006), and higher incidence of true clonal evolution in Ph-positive metaphase (22.9% vs. 9.1%, <i>p</i>\xe2\x80\x89=\xe2\x80\x89.017). Additionally, patients with Ph- CAs had worse rates of complete cytogenetic remission (76% vs. 86%, <i>p</i>\xe2\x80\x89=\xe2\x80\x89.0091), major molecular remission (55% vs. 76%, <i>p</i>\xe2\x80\x89=\xe2\x80\x89.001), progression-free survival (47% vs. 86%, <i>p</i>\xe2\x80\x89&lt;\xe2\x80\x89.001), but a similar overall survival rates compared to those in patients without Ph- CAs. In conclusion, Ph- CAs may predict worse response to TKI therapies and survival in patients with CP-CML, thus requiring close cytogenetic monitoring.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Sheng</LastName>\n                    <ForeName>Guangying</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Xue</LastName>\n                    <ForeName>Mengxing</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wang</LastName>\n                    <ForeName>Qinrong</ForeName>\n                    <Initials>Q</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Wen</LastName>\n                    <ForeName>Lijun</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chen</LastName>\n                    <ForeName>Suning</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Xinyou</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Hematology, The Second Clinical Medical College (Shenzhen People\'s Hospital), Jinan University, Shenzhen, PR China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yang</LastName>\n                    <ForeName>Xiaofei</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, PR China.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>07</Month>\n                <Day>08</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Leuk Lymphoma</MedlineTA>\n            <NlmUniqueID>9007422</NlmUniqueID>\n            <ISSNLinking>1026-8022</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Chronic myeloid leukemia</Keyword>\n            <Keyword MajorTopicYN="Y">Philadelphia chromosome-negative metaphases</Keyword>\n            <Keyword MajorTopicYN="Y">monosomy-7 and del(7q)</Keyword>\n            <Keyword MajorTopicYN="Y">prognosis</Keyword>\n            <Keyword MajorTopicYN="Y">tyrosine kinase inhibitors</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>10</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>10</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>7</Month>\n                <Day>9</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31282805</ArticleId>\n            <ArticleId IdType="doi">10.1080/10428194.2019.1636984</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'